ERBB2 and breast carcinoma: In HER2-positive breast cancer, integrating genomic, transcriptomic, and epigenomic data revealed that methylation of the HSD17B4 gene as a biomarker predicts sensitivity to HER2-targeted therapies, providing new insights for improving treatment precision [174].